The Second Appellate District reversed a judgment and remanded. The court held that the trial court erred, in a product liability action, when it struck the plaintiff’s expert testimony based on the ...
$1,520,000 of TAKEDA PHARMACEUTICALS AMERICA INC lobbying was just disclosed, from Q2 of 2025, in a new Lobbying Disclosure Act filing. This included lobbying on issues like: "FY 2025 Budget ...
The results bolster confidence in Takeda’s two-dose regimen, especially as countries grapple with record dengue outbreaks ...
Joining a list that recently includes Pfizer, UCB and WuXi AppTec, Takeda Pharmaceuticals is the latest drugmaker to pull out of prominent industry lobbying group the Biotechnology Innovation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback